Transchem Ltd Stock Price Today (NSE: TRANSCHEM)

Transchem Ltd

366.50+0.00 (+0.00%)
Market Closed

Fundamental Score

...

Transchem Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Transchem Ltd share price today is 366.50, up +0.00% on NSE/BSE as of 22 September 2026. Transchem Ltd (TRANSCHEM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 425.77 (Cr). The 52-week high for TRANSCHEM share price is 370.25 and the 52-week low is 57.95. At a P/E ratio of 99.02x, TRANSCHEM is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 5.28% and a debt-to-equity ratio of 0.00.

Transchem Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
366.50
Low
284.65
Volume
7.1K
Change
-2.87%

Transchem Ltd share price chart: -2.87% return over the past month. 52-week high ₹370.25, 52-week low ₹57.95.

Transchem Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
331.00334.25324.90333.155.15K (Cr)
326.05335.00321.30331.4511.68K (Cr)
324.00325.20316.00321.601.29K (Cr)
328.00328.00322.00323.901.01K (Cr)
323.00329.50315.00326.204.86K (Cr)
327.00328.00312.00325.553.79K (Cr)
326.80340.00313.00327.954.06K (Cr)
325.15334.65318.70326.804.24K (Cr)
319.00329.95307.05318.753.99K (Cr)
310.00322.60306.00319.0010.31K (Cr)

Transchem Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
290.05340.00285.65333.15+14.86%
335.30370.25284.65300.65-10.33%
235.25356.15234.65342.10+45.42%
165.00224.05158.30224.05+35.79%
165.00189.65141.85165.00+0.00%
181.00181.00148.90162.65-10.14%
165.00184.65130.05184.65+11.91%
186.75194.25152.20170.00-8.97%
100.48183.11100.48183.11+82.24%
68.0095.7063.0195.70+40.74%
61.0174.0257.9567.42+10.51%
68.8875.8960.0061.00-11.44%

Returns & Performance

Poor

Return on Equity (ROE)

5.28%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

6.89%

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Transchem Ltd Valuation Check

Poor

Price to Earnings (P/E)

99.02x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

56.45%

% shares held by company founders/management

Poor

FII Holding

0.03%

% shares held by foreign institutional investors

Poor

DII Holding

0.01%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

186.30%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-100.00%

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

13.93%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

13.93%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.00x

Total debt ÷ equity. Below 0.5 = financially healthy

Interest Coverage Ratio

N/A

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

20.36 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Transchem Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of TRANSCHEM across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Robust Profit Growth (186.30%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Healthy Liquidity Position (Current Ratio: 257.86)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Balanced Promoter Holding (56.45%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

7 factors identified

Below-Average Return on Equity (5.28%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (6.89%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Premium Valuation Risk (P/E: 99.02x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

High Price-to-Book Ratio (5.66x)

Observation: Trading at significant premium to book value.

Analysis: High P/B ratios may indicate overvaluation relative to asset base.

Revenue Contraction (-100.00%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Limited Institutional Interest (FII+DII: 0.04%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Transchem Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Transchem Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
35.7/100
367
₹425.77
99.0
Average
5.28%
Poor
6.89%
Poor
0.0
Excellent
13.93%
Good
0.00%
66.4/100
1861
₹446509.73
36.9
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9439
₹250120.25
85.6
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4930
₹166860.78
78.8
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1118
₹111556.44
24.9
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1373
₹110942.04
32.9
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1945
₹105078.63
96.0
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1668
₹95999.74
26.1
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
41/100
1143
₹95440.50
29.5
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
83.4/100
2078
₹95007.40
17.2
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
61.5/100
2238
₹92445.92
45.2
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Transchem Ltd PE Ratio History

Historical price-to-earnings ratio for TRANSCHEM — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20254.27₹183.1142.9x
FY 20243.43₹51.4815x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Transchem Ltd Quarterly Performance

Latest quarterly metrics for TRANSCHEM — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-100.00%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

186.30%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

13.93%

Compounded annual net profit growth over 5 years

Transchem Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for TRANSCHEM — calculated from daily price history

73RSI 14
Overbought — RSI 73

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
323
▲ Price above SMA 50 — Short-term bullish
SMA 200
200
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
7K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Transchem Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Transchem Ltd (TRANSCHEM) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Transchem Ltd

Loading latest quarterly results...

About TRANSCHEM (Transchem Ltd)

Transchem Ltd is a dynamic, research-driven pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies. We are focused on address...ing unmet medical needs in key therapeutic areas such as oncology, immunology, and central nervous system disorders. Our state-of-the-art research facilities and collaborative partnerships with leading academic institutions and biotech firms enable us to push the boundaries of pharmaceutical science. We pride ourselves on a commitment to scientific excellence, ethical practices, and patient-centricity, striving to improve the lives of individuals worldwide through the power of transformative medicines. Transchem's pipeline encompasses a diverse portfolio of novel drug candidates, from early-stage preclinical assets to late-stage clinical programs. At Transchem, we are driven by a passionate team of scientists, clinicians, and business professionals with a shared vision of creating breakthrough pharmaceuticals. Our core values are rooted in integrity, innovation, and collaboration, fostering a culture where creativity thrives and every individual is empowered to make a meaningful contribution. We maintain a strong focus on precision medicine, leveraging advanced technologies like genomics and bioinformatics to tailor treatments to individual patient profiles. This approach allows us to maximize therapeutic efficacy and minimize adverse effects. Furthermore, we are committed to sustainable and responsible practices throughout our operations, minimizing our environmental impact and supporting the communities we serve. TRANSCHEM actively seeks strategic alliances and licensing opportunities to expand our product portfolio and accelerate the delivery of novel therapies to patients. Our experienced business development team is dedicated to identifying and evaluating promising drug candidates and technologies that align with our strategic priorities. We are committed to building long-term, mutually beneficial partnerships with other pharmaceutical companies, biotech firms, and academic institutions. By combining our expertise and resources, we can collectively address the most pressing healthcare challenges and improve patient outcomes globally. TRANSCHEM is poised to emerge as a leader in the pharmaceutical industry, driven by our unwavering commitment to innovation, patient care, and global health.

Company Details

Symbol:TRANSCHEM
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Mahesh Suresh Rananavre
Whole Time Director
Ms. Sarita Maharao
Chief Financial Officer
Ms. Neeraja Deepak Karandikar
Compliance Officer & Company Secretary

TRANSCHEM Share Price: Frequently Asked Questions

What is the current share price of Transchem Ltd?

Transchem Ltd (TRANSCHEM) trades at ₹366.50 on NSE and BSE. Market cap ₹425.77 (Cr). Educational data only.

What is the P/E ratio of Transchem Ltd?

Transchem Ltd has a P/E of 99.02x vs industry average 34.89x.

What is the Bull Run score for Transchem Ltd?

Transchem Ltd has a Bull Run score of 35.7/100 based on 25+ financial parameters.

Does Transchem Ltd pay dividends?

Transchem Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Transchem Ltd?

Transchem Ltd has ROE of 5.28%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Transchem Ltd?

Transchem Ltd has debt-to-equity of 0.00.

Is Transchem Ltd a good investment?

Bull Run gives Transchem Ltd a score of 35.7/100. This is not investment advice — consult a SEBI-registered advisor.